<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381793</url>
  </required_header>
  <id_info>
    <org_study_id>PAN study 2019-10</org_study_id>
    <nct_id>NCT04381793</nct_id>
  </id_info>
  <brief_title>Treatment of CFS &amp; Fibromyalgia With Recovery Factors</brief_title>
  <official_title>Treatment of CFS &amp; Fibromyalgia With Recovery Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Practitioners Alliance Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Practitioners Alliance Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will explore if Recovery Factors improve symptoms in fibromyalgia and chronic
      fatigue syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive four tablets twice a day (three times a day for five day loading dose),
      taking the treatment for 5 - 6 weeks. Subjects will receive four tablets twice a day (three
      times a day for five day loading dose), taking the treatment for 5 - 6 weeks. The treatment
      is a unique nutritional peptide mix derived from porcine serum
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Anticipated">July 4, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 4, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open pilot study to assess efficacy and antibody effects</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS</measure>
    <time_frame>6 weeks</time_frame>
    <description>Composite VAS (1-10) for Fatigue, Pain, Cognition, Sleep and overall well-being</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>antibody titres</measure>
    <time_frame>10 weeks</time_frame>
    <description>Total IgG and IgG 1-4 subsets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FIQ-R</measure>
    <time_frame>6 weeks</time_frame>
    <description>Fibromyalgia severity scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Chronic Fatigue Syndrome</condition>
  <arm_group>
    <arm_group_label>Assessing clinical efficacy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive four tablets twice a day (three times a day for five day loading dose), taking the treatment for 5 - 6 weeks. The treatment is a unique nutritional peptide mix derived from porcine serum. Pre-and post FIQ-R and VA symptom score will be assessed as well as overall well-being. In a subgroup, pre-and post antibody levels will also be checked. Phase 1 will be a group of 60 subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Recovery Factors</intervention_name>
    <description>Porcine serum amino acid/peptide</description>
    <arm_group_label>Assessing clinical efficacy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet ACR 2010 amended Fibromyalgia criteria or CDC CFS Criteria Overall well being
             score of 5 of less (on 0-10 VAS)

        Exclusion Criteria:

        Pregnant Clotting disorders

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaetano Morello, ND</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woman's Hospital in Vancouver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob Teitelbaum, MD</last_name>
    <phone>410-573-5389</phone>
    <email>FatigueDoc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jacob Teitelbaum MD</name>
      <address>
        <city>Kailua</city>
        <state>Hawaii</state>
        <zip>96740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Teitelbaum</last_name>
      <phone>410-573-5389</phone>
      <email>FatigueDoc@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

